Press Releases Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 20:01:52 18/05/2026 BST			5-day change	1st Jan Change
156.70 ^USD	-1.09%		+3.92%	+10.34%

05:36pm	Neurocrine Biosciences, Inc. completed the acquisition of Soleno Therapeutics, Inc. from Anish Bhatnagar, James Mackaness, and others.	CI
02:51pm	Neurocrine Biosciences completes acquisition of Soleno Therapeutics	RE

Press Releases

01:48pm	Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics	PR
05-06	Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia	PR
05-05	Neurocrine Biosciences : Presentation (NBIX Q1 2026 Earnings Presentation Final 0556)	PU
05-05	Neurocrine: Q1 Earnings Snapshot	AQ
05-05	Neurocrine Biosciences Reports First-Quarter 2026 Financial Results	PR
05-05	Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026	PR
05-04	Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment	PR
05-04	Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist	PR
05-01	Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia	PR
04-29	Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale	PR
04-22	Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia	PR
04-15	Neurocrine Biosciences : 2026 Proxy Statement (NBIX 2026 Proxy Statement)	PU
04-15	Neurocrine Biosciences : 2025 Annual Report*	PU
04-14	Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results	PR
04-14	Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR	PR
04-06	Neurocrine Biosciences : Presentation (FINAL NBIX SLNO Investor Presentation 0466 Final)	PU
04-06	Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio	PR
03-26	Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings	PR
03-24	Biocom Appoints New Members to Its Board of Directors	AQ
03-17	Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer	PR
03-10	Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum	PR
02-24	Neurocrine Biosciences to Present at Upcoming Investor Conferences in March	PR
02-12	Neurocrine Biosciences : Presentation (Final NBIX Q4 and FY 2025 Earnings Presentation 02 WT5vGfd16)	PU
02-11	Neurocrine Biosciences : Presentation (Final NBIX Q4 and FY 2025 Earnings Presentation 0216)	PU
02-11	Neurocrine: Q4 Earnings Snapshot	AQ